A Bold Step Forward in Cell Therapy Manufacturing
Made Scientific, a Princeton-based clinical and commercial cell therapy contract development and manufacturing organization (CDMO), is making waves in the healthcare sector by announcing a significant partnership with Clearwater, Florida's CARR Biosystems. This alliance aims to advance cell therapy manufacturing through the deployment of CARR's advanced UniFuge technology.
Transforming Cell Therapy Processes
The UniFuge system, known for its low-shear centrifugal capabilities, will be utilized in Made Scientific's operations for cell harvesting, washing, and concentration. This cutting-edge platform is tailored specifically for large-scale manufacturing needs, focusing on producing mesenchymal stem cells (MSCs) and feeder cells. Syed T. Husain, CEO of Made Scientific, underscores the importance of integrating automated solutions into the manufacturing process, emphasizing that scaling the whole procedure is vital for commercial readiness.
Ensuring High Viability and Recovery
What makes the UniFuge platform particularly exciting is its ability to maintain cell viability and product recovery even during large-scale operations. Its versatility—accommodating volumes from milliliters to over 2,000 liters—gives manufacturers the flexibility needed to ensure consistency from development through to good manufacturing practices (GMP).
Supporting Allogeneic Therapy Scalability
This partnership not only improves manufacturing processes but also sets the stage for better allogeneic programs. With the integration of UniFuge's closed, automated systems, Made Scientific can provide their clients with robust solutions that will enhance productivity while helping to mitigate risks associated with scaling up production. The collaboration is truly a win-win that promotes innovation in local healthcare applications!
Local Impact and Future Directions
This partnership marks a pivotal moment for healthcare in Northern NJ, particularly as the demand for advanced cell therapies grows. The efficiencies gained from the collaboration could ultimately translate into faster patient access to cutting-edge treatments. As they move forward, joint development studies utilizing CARR’s UFMini system will streamline the transition from early-phase manufacturing to larger operations.
Moving Towards a Healthier Tomorrow
The advancements in cell therapy manufacturing driven by this partnership signify a positive trajectory for healthcare in communities across Sussex County NJ. As the implications of this collaboration unfold, we encourage local residents and stakeholders to stay informed about this exciting development that has the potential to make a real difference.
Write A Comment